Valiant Laboratories Ltd

Valiant Laborato Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Valiant Laboratories Ltd

₹ 77.4 -3.22%
29 May - close price
valiantlabs.in BSE: 543998 NSE: VALIANTLAB
About

Incorporated in 1980, Valiant Laboratories
Ltd manufactures and deals in Pharmaceuticals and speciality chemicals[1]

Key Points

Business Overview:[1][2]
VLL is in the active pharmaceutical ingredient manufacturing business. It manufactures finished dosage forms of paracetamol API viz. Tablets, Capsules, and Other medications. Paracetamol API is a key ingredient used to treat a variety of conditions including Headache, Arthritis, Muscle Aches, Toothache, Backache, Cold, and Fever

Website BSE NSE - BE
  • Market Cap ₹ 434 Cr.
  • Current Price ₹ 77.4
  • High / Low ₹ 116 / 49.5
  • Stock P/E
  • Book Value ₹ 57.2
  • Dividend Yield 0.00 %
  • ROCE 0.75 %
  • ROE -1.20 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company has reduced debt.
  • Company is expected to give good quarter

Cons

  • Company has low interest coverage ratio.
  • Company has a low return on equity of -1.41% over last 3 years.
  • Earnings include an other income of Rs.2.32 Cr.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
89.92 51.41 59.55 40.52 30.59 18.88 21.48 35.23 57.79 46.82 46.20 52.46 91.98
81.30 47.59 60.94 46.83 35.12 21.27 28.22 34.61 53.97 44.43 46.12 53.35 87.17
Operating Profit 8.62 3.82 -1.39 -6.31 -4.53 -2.39 -6.74 0.62 3.82 2.39 0.08 -0.89 4.81
OPM % 9.59% 7.43% -2.33% -15.57% -14.81% -12.66% -31.38% 1.76% 6.61% 5.10% 0.17% -1.70% 5.23%
1.72 2.44 2.96 1.78 2.50 2.81 3.36 1.58 -2.31 0.66 0.87 0.63 0.17
Interest 0.03 0.02 0.02 0.02 0.02 0.05 0.01 0.06 0.05 0.07 0.14 0.68 1.01
Depreciation 0.44 0.46 0.49 0.49 0.52 0.53 0.52 0.52 0.52 0.53 0.53 2.05 2.93
Profit before tax 9.87 5.78 1.06 -5.04 -2.57 -0.16 -3.91 1.62 0.94 2.45 0.28 -2.99 1.04
Tax % 20.67% 26.12% 25.47% -30.75% -51.75% 218.75% 21.23% -44.44% 25.53% 25.71% 25.00% 136.12% -68.27%
7.83 4.27 0.79 -3.50 -1.24 -0.51 -4.74 2.35 0.70 1.82 0.20 -7.06 1.76
EPS in Rs 1.92 1.05 0.19 -0.64 -0.23 -0.09 -0.87 0.43 0.13 0.34 0.04 -1.30 0.32
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Mar 2024 Mar 2025 Mar 2026
334 182 133 237
299 190 138 231
Operating Profit 35 -8 -5 6
OPM % 11% -5% -4% 3%
5 10 5 2
Interest 0 0 0 2
Depreciation 2 2 2 6
Profit before tax 38 -1 -2 1
Tax % 24% -142% 46% 525%
29 0 -2 -3
EPS in Rs 7.13 0.06 -0.41 -0.60
Dividend Payout % 0% 0% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: -11%
TTM: 78%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: 3%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: -20%
Return on Equity
10 Years: %
5 Years: %
3 Years: -1%
Last Year: -1%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 33 43 43 54
Reserves 68 193 191 257
60 77 122 46
52 29 45 107
Total Liabilities 213 343 401 464
48 50 48 227
CWIP 1 43 156 6
Investments 34 38 0 28
130 212 197 202
Total Assets 213 343 401 464

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Mar 2024 Mar 2025 Mar 2026
56 2 1 -10
-55 -144 -53 7
-1 152 45 2
Net Cash Flow -0 10 -7 -1
Free Cash Flow 18 -44 -112 -45
CFO/OP 185% -11% 25% -147%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 97 92 197 144
Inventory Days 17 22 13 84
Days Payable 62 56 128 174
Cash Conversion Cycle 52 57 82 54
Working Capital Days 70 106 156 156
ROCE % -2% -1% 1%

Insights

In beta
Mar 2022 Mar 2023 Mar 2024 Mar 2025
Average Revenue per MT (Paracetamol)
INR ・Standalone data

Log in to view insights

Please log in to see hidden values.

Login
Export Sales Mix
% ・Standalone data
Installed Manufacturing Capacity (Paracetamol)
MTPA ・Standalone data
Number of Permanent Employees
Count ・Standalone data
Paracetamol Sales Volume
Metric Tons (MT) ・Standalone data

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
74.94% 74.94% 74.94% 74.94% 74.94% 74.94% 74.94% 74.94% 74.94% 74.94% 74.94%
8.64% 7.08% 3.48% 1.89% 0.00% 0.00% 0.64% 0.63% 0.02% 0.01% 0.20%
1.76% 0.43% 0.00% 0.00% 0.00% 0.00% 0.00% 0.46% 0.00% 0.00% 0.00%
14.66% 17.54% 21.58% 23.18% 25.06% 25.06% 24.42% 23.97% 25.05% 25.05% 24.87%
No. of Shareholders 37,43415,82114,91414,24915,18915,69215,03614,43215,07514,91014,657

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings